RT Journal Article
SR Electronic
T1 Quantitative LC-MS study of compounds found predictive of COVID-19 severity and outcome
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.17.23287401
DO 10.1101/2023.03.17.23287401
A1 Roberts, Ivayla
A1 Muelas, Marina Wright
A1 Taylor, Joseph M.
A1 Davison, Andrew S.
A1 Winder, Catherine L.
A1 Goodacre, Royston
A1 Kell, Douglas B.
YR 2023
UL http://medrxiv.org/content/early/2023/03/17/2023.03.17.23287401.abstract
AB INTRODUCTION Since the beginning of the SARS-CoV-2 pandemic in December 2019 multiple metabolomics studies have proposed predictive biomarkers of infection severity and outcome. Whilst some trends have emerged, the findings remain intangible and uninformative when it comes to new patients.OBJECTIVES In this study, we accurately quantitate a subset of compounds in patient serum that were found predictive of severity and outcome.METHODS A targeted LC-MS method was used in 46 control and 95 acute COVID-19 patient samples to quantitate the selected metabolites. These compounds included tryptophan and its degradation products kynurenine and kynurenic acid (reflective of immune response), butyrylcarnitine and its isomer (reflective of energy metabolism) and finally 3’,4’-didehydro-3’-deoxycytidine, a deoxycytidine analogue, (reflective of host viral defence response). We subsequently examine changes in those markers by disease severity and outcome relative to those of control patients’ levels.RESULTS & CONCLUSION Finally, we demonstrate the added value of the kynurenic acid / tryptophan ratio for severity and outcome prediction and highlight the viral detection potential of ddhC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by Biotechnology and Biological Sciences Research Council (Grant Number BB/V003976/1), Novo Nordisk Foundation (grant NNF20CC0035580) and Medical Research Council (grant reference: MR/S010483/1) provided to MAP/UK project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approval for the use of serum samples and associated metadata in this study was obtained from North West Haydock research ethics committee (REC ref: 20/NW/0332).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesUHPLC-MS data for the quantitative study in RAW format is freely available in the MetaboLights repository (Haug et al., 2020) with study identifier MTBLS7429 (https://www.ebi.ac.uk/metabolights/).